New developments in systemic therapy for hepatocellular carcinoma

This item is provided by the institution :

Repository :
Annals of Gastroenterology
see the original item page
in the repository's web site and access all digital files if the item*

2008 (EN)
New developments in systemic therapy for hepatocellular carcinoma (EN)

Dourakis, S.P.

Hepatocellular carcinoma (HCC) accounts for 90% of all primary liver cancers. ΗCC is the fifth most common malignancy and the third cause of cancer death globally (more than 500.000 cases yearly) with most deaths occurring within one year of diagnosis.1,2 In 90-95% οf cases, HCC is developed in cirrhotic liver. Liver transplantation (from cadaveric or living donors), surgical resection, percutaneous ethanol injection, transcatheter arterial chemoembolizatin (TACE) and radio-frequency (RF) thermal ablation microwaves achieve a relatively high response rate only in carefully selected candidates with small (diameter < 5 cm) tumors. Hepatic reserve often dictates the therapeutic options. Systemic therapy is appropriate for patients with advanced unresectable disease who are unsuitable for locoregional therapy and carry dismal prognosis. Nevertheless, up until now, there have been multitudes of negative systemic therapy trials for advanced HCC.3 So, in 60-75% οf HCC cases in Europe and the USA, no therapy short of palliative approaches was given to patients.4,5,6,7 (EN)




Hellenic Society of Gastroenterology (EN)

Annals of Gastroenterology; Volume 21, No 2 (2008); 83-87 (EN)

*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)